Skip to main content
Skip to main content
Go to homepage

Rimegepant for migraine in pediatric patients

Safety and efficacy of Rimegepant for the treatment of migraine in pediatric patients ≥6 to <18 years of age

Description:

View complete study information here.

Who May Qualify?:

View complete study information here.

Who Does Not Qualify:

View complete study information here.

Interested in participating?
We are currently recruiting
Study Sponsor:

Biohaven Pharmaceuticals, Inc.

Full IRB Study Title:
Phase 3, multicenter, randomized, double-blind, group sequential, placebo-controlled study to assess efficacy and safety of rimegepant for the treatment of migraine (with or without aura) in children and adolescents ≥ 6 to <18 years of age
IRB Study ID:
1737932
If you are interested in this study or have questions about your child's eligibility, please contact:

Chad Gentry: cgentry@akronchildrens.org,  330-543-9809

Jessica Kracker: jkracker@akronchildrens.org,  330-543-0846

Lead Investigator
M. Cristina Victorio, MD

Director, Headache Program; Pediatric Neurologist
NeuroDevelopmental Science CenterHeadache ClinicPediatric Neurology